RC
LFCR icon

RegentAtlantic Capital’s Lifecore Biomedical LFCR Stock Holding History

RegentAtlantic Capital’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,000
Closed -$13.8K – 666
2014
Q4 		$13.8K Buy
+1,000
New +$12.9K ﹤0.01% 835

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
KG
Killen Group Berwyn, Pennsylvania $866M AUM 0.25% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RegentAtlantic Capital's LFCR Position: Q1 2015 in Review

RegentAtlantic Capital sold out of Lifecore Biomedical (LFCR) in Q1 2015, closing a stake of 1,000 shares — an estimated $13.8K sold.

RegentAtlantic Capital first reported a position in LFCR in Q4 2014 and held it in 1 quarter. The position peaked at $13.8K in Q4 2014. 99 funds tracked by Wall St. Rank hold LFCR as of Q1 2015.

  • RegentAtlantic Capital reported no remaining Lifecore Biomedical position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 1,000 Lifecore Biomedical shares in Q1 2015, an estimated $13.8K.
  • RegentAtlantic Capital first reported a position in Lifecore Biomedical in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's Lifecore Biomedical position peaked at $13.8K in Q4 2014.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.